Voyager Therapeutics Inc (NASDAQ:VYGR) insider Bernard Ravina sold 3,630 shares of the company’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $16.40, for a total value of $59,532.00. Following the transaction, the insider now directly owns 7,353 shares of the company’s stock, valued at $120,589.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Bernard Ravina also recently made the following trade(s):

  • On Monday, December 11th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $13.63, for a total value of $74,828.70.
  • On Friday, November 10th, Bernard Ravina sold 5,490 shares of Voyager Therapeutics stock. The stock was sold at an average price of $13.26, for a total value of $72,797.40.

Shares of Voyager Therapeutics Inc (NASDAQ VYGR) opened at $18.27 on Friday. Voyager Therapeutics Inc has a fifty-two week low of $8.10 and a fifty-two week high of $25.99. The firm has a market capitalization of $468.92 and a PE ratio of -6.43.

VYGR has been the subject of several analyst reports. Chardan Capital reaffirmed a “hold” rating and set a $17.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Canaccord Genuity started coverage on Voyager Therapeutics in a report on Friday, October 27th. They issued a “buy” rating and a $35.00 target price for the company. Zacks Investment Research raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 6th. ValuEngine raised Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Finally, Raymond James Financial started coverage on Voyager Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $35.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $26.90.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Iguana Healthcare Management LLC purchased a new stake in Voyager Therapeutics during the 3rd quarter valued at approximately $515,000. Point72 Asset Management L.P. purchased a new stake in Voyager Therapeutics during the 3rd quarter valued at approximately $2,695,000. Dimensional Fund Advisors LP raised its stake in Voyager Therapeutics by 7.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 105,914 shares of the company’s stock valued at $2,181,000 after acquiring an additional 7,786 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Voyager Therapeutics by 71.5% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 49,788 shares of the company’s stock valued at $1,026,000 after acquiring an additional 20,753 shares during the last quarter. Finally, Mckinley Capital Management LLC Delaware purchased a new stake in Voyager Therapeutics during the 3rd quarter valued at approximately $1,412,000. 35.97% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Bernard Ravina Sells 3,630 Shares of Voyager Therapeutics Inc (VYGR) Stock” was published by American Banking News and is the property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/01/12/bernard-ravina-sells-3630-shares-of-voyager-therapeutics-inc-vygr-stock.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.